| Abstract | It is estimated that 50 million individuals worldwide live with Alzheimer's disease (AD), a neurodegenerative progressive disorder that, along with other chronic dementias, cost the United States $355 billion in 2021. Previous research links AD with amyloid beta (Aß) aggregation in the brain. Possible therapeutic drugs, including antioxidants and metal chelating agents, need efficient delivery systems that can cross the blood-brain barrier and release drugs appropriately. Recent discoveries in nanoscale materials as targeted drug delivery and controlled release agents have shown that such materials can release therapeutic drugs in a slow manner and increase efficacy. Chief among these carriers are porous materials with high surface areas because of their tunable pore structure, surface chemistry and drug loading capacity. This project focuses on using porous silicon derivatives as a carrier because, in addition to the above properties, it is a known biocompatible material.This research deals with developing efficient protocols for loading mesoporous silica (pSiO2) with selected metal ion binding agents through systematic manipulation of external variables in order to achieve the highest percentage of loading. Once this has been determined, release and complexation studies are conducted. Known spectrophotometric methods are used to monitor diffusion over time and evaluate the profile of the sustained release. Different derivatives of macrocycles are loaded and released to determine the effects of structural characteristics. The macrocyclic molecule pyclen is the first tested candidate, followed by its dimer form, and finally a halogen substituted derivative. Stoichiometric complexation ratios with copper ions are then measured. Developing a slow and steady rate at which drugs capable of inhibiting neurotoxic Aß aggregates in the brain can be released should be more effective and lead to more promising solutions for AD. |
